Bioage advances apelin receptor agonist program with option to Jikang’s nanobody

June 4, 2025

Bioage Labs Inc. is advancing its apelin receptor (APJ) agonist programs for obesity and other indications, and has entered into an option agreement with Jikang Therapeutics to license a novel APJ agonist nanobody.

BioWorld Science Endocrine/metabolic

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 17, 2025.

Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA

BioWorld

During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...

23andme founder-led group outbids Regeneron for company

BioWorld

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...

Elevidys’ second liver death hits Sarepta, sends DMD ripples

BioWorld

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...